Intarcia Therapeutics clinical trials
Also known as BioMedicines.
The registry lists 22 studies whose lead sponsor is Intarcia Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 7, 2019.
Our grouping of 2 registry names, not the registry’s. See them and correct one ↓
- 22studies on the registry
- 0open to participants now
What it is testing
The drugs Intarcia Therapeutics’ studies test, most studies first; none is open now — 11 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- Exenatide7 in phase 30 open · 10
- atamestane4 in phase 30 open · 4
- Toremifene4 in phase 30 open · 4
- Letrozole2 in phase 30 open · 2
- 0 open · 1
- 0 open · 1
- empagliflozin1 in phase 30 open · 1
- glimepiride1 in phase 30 open · 1
- 0 open · 1
- 0 open · 1
All 22 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 08
- 09
- 10
- 11
- 12
- 713
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 6 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Intarcia Therapeutics.
- Intarcia Therapeutics21 studiesSame company
Something wrong?
- BioMedicines1 studySame company
Something wrong?
Focus areas
Conditions Intarcia Therapeutics leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 22 of 22.
- Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on MetforminTerminatedNCT03060980Phase 3
- A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1cTerminatedNCT01785771Phase 3
- Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving LiraglutideCompletedNCT02638805Phase 3
- A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650CompletedNCT01455896Phase 3
- Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied DrugsCompletedNCT02641899Phase 1
- Study of the Effects of Intravenous Exenatide on Cardiac RepolarizationCompletedNCT02650479Phase 1
- Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal SubjectsCompletedNCT02320045Phase 1
- A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 DiabetesCompletedNCT01455870Phase 3
- Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female SubjectsCompletedNCT02641990Phase 1
- A Study to Evaluate ITCA 650 for the Treatment of Type 2 DiabetesCompletedNCT01455857Phase 3
- Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast CancerCompletedNCT00044291Phase 3
- Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes MellitusCompletedNCT00943917Phase 2
- Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast CancerTerminatedNCT00010322Phase 3
- Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 DiabetesCompletedNCT01798264Phase 1
- Biomed 101 and Interleukin-2 in Treating Patients With Kidney CancerCompletedNCT00004890Phase 1
Sponsor listed in the registry: BioMedicines
- A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 DiabetesWithdrawnNCT01455922Phase 3
- A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 DiabetesWithdrawnNCT01455909Phase 3
- A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 DiabetesWithdrawnNCT01455883Phase 3
- Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior TreatmentCompletedNCT00519792Phase 1
- Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast CancerTerminatedNCT00267553Phase 3
- The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast CancerTerminatedNCT00097344Phase 3
- Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis CCompletedNCT00097045Phase 2